JLS Fund: Investing in Neuromedicine with Top Decline Performance

Founded in 2019, JLS Fund is a unique venture capital fund leveraging the paradigm shift taking place in precision neuromedicine driven by science, technology, and data.

We finance and help build companies that translate breakthroughs in neuroscience, technology, and data into outcomes for patients—and value for strategic acquirers.

Investments & Advisories

Enthea

Mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy.

ProNovo

ProNovo Therapeutics, leveraging emerging science and cutting-edge technology, to develop novel, precision therapeutics to address urgent unmet needs in the treatment of neuropsychiatric disorders such as Major Depressive Disorder and Schizophrenia.

Psilera Bioscience

Reimagines psychoactive natural products as the building blocks for the next generation of neurological products

Tripp

An award-winning breakthrough wellness platform

Immunis Biomedical

Immunis is a clinical-stage biotech company developing multi-active biologics with immune modulating factors that can address age-related diseases and immune dysregulation.